Ascendis Pharma A/S (NASDAQ:ASND) Shares Purchased by Gilbert & Cook Inc.

Gilbert & Cook Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 72.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,421 shares of the biotechnology company’s stock after purchasing an additional 1,858 shares during the period. Gilbert & Cook Inc.’s holdings in Ascendis Pharma A/S were worth $609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC raised its stake in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S in the 3rd quarter valued at $30,000. GAMMA Investing LLC lifted its position in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after purchasing an additional 228 shares during the period. Finally, Avior Wealth Management LLC lifted its stake in Ascendis Pharma A/S by 3.0% in the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock valued at $1,226,000 after acquiring an additional 240 shares during the last quarter.

Ascendis Pharma A/S Stock Up 0.4 %

Shares of ASND stock traded up $0.54 during trading hours on Thursday, hitting $128.09. 1,516 shares of the company’s stock traded hands, compared to its average volume of 435,750. The stock has a market cap of $7.77 billion, a PE ratio of -15.85 and a beta of 0.65. The stock’s 50 day simple moving average is $133.53 and its 200 day simple moving average is $133.03. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ASND shares. UBS Group assumed coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Stifel Nicolaus raised their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.57.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.